GlassScriptPhysician profile
Yosef Krespi
NPI 1417042565
$1,111.59
in general payments reported to CMS, 2019-2025
7 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $101 · 2023: $252 · 2024: $365 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $352.76 | 2022-2023 | Trudi Nav Cable |
| Cambridge Interventional LLC | $239.57 | 2024 | Crf |
| Integra Lifesciences Corporation | $186.39 | 2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Airsupra |
| Smith+Nephew, INC. | $107.40 | 2025 | Rf20000, Halo |
| Olympus America INC. | $100.47 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$37,931.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yosef Krespi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.